Cholesterol and lipoproteins

Heart disease is the single biggest barrier to a long life, and the cholesterol that drives it is widely misunderstood: what ages your arteries is not the number on one panel but the lifelong number of cholesterol-carrying particles your blood vessels have been exposed to. The famous cholesterol "paradoxes" don't overturn that — they just confuse people who read a snapshot as if it were the whole movie.

Cholesterol itself is not a villain — it is an essential building block of every cell membrane and the raw material for hormones, vitamin D, and bile. The problem is transport. Cholesterol does not dissolve in blood, so the body wraps it in particles called lipoproteins. Some of those particles get trapped in artery walls and start the slow, decades-long process of atherosclerosis. Understanding which particles matter, and why, explains nearly every cholesterol-related recommendation on the rest of this site — and dissolves most of the apparent contradictions that circulate online.

Particles, not cholesterol — why apoB is the real signal

Strong. The standard lipid panel reports the mass of cholesterol carried inside particles: total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol, and triglycerides. But atherosclerosis is not caused by cholesterol mass — it is caused by the number of artery-penetrating particles. Every atherogenic particle (LDL, its precursors VLDL and IDL, and lipoprotein(a)) carries exactly one molecule of apolipoprotein B (apoB) on its surface. Measuring apoB therefore counts those particles directly, and it predicts heart risk more reliably than LDL-C: in a pooled analysis of 12 studies covering about 233,000 people, apoB was the strongest of the three markers and LDL-C the weakest [1]. Whether apoB also beats non-HDL cholesterol, which comes free with any standard panel, is less clear. In 94,398 Danish adults not taking cholesterol-lowering drugs, the two predicted heart attacks and other artery-disease events about equally well, and each added some information beyond the other [2], whereas a separate UK Biobank analysis of nearly 300,000 adults (below) found that apoB absorbed non-HDL cholesterol's signal. Not every particle is equally harmful either: genetic evidence suggests the larger triglyceride-rich remnant particles are roughly four times as damaging per particle as LDL [3].

This matters because the cholesterol number and the particle count often disagree. When particles are small, dense, and cholesterol-depleted — the pattern seen in insulin resistance and metabolic syndrome — LDL-C can look reassuringly normal while the particle count is dangerously high. When the two disagree, risk follows apoB, though the gap is modest: in about 375,000 UK Biobank adults without heart disease and not on lipid-lowering drugs, the roughly 1 in 10 whose apoB ran higher than their LDL-C would predict had about 6% to 11% higher risk of major cardiovascular events such as heart attack and stroke (HR 1.06-1.11, depending on adjustment), while those whose apoB ran lower had lower risk [4]. In nearly 300,000 UK Biobank adults, once apoB was in the model the residual risk carried by LDL-C, non-HDL-C, and triglycerides all vanished — apoB captured what they were each pointing at.[5] Discordance is common, not rare: across studies, roughly 5% to 25% of people carry more apoB particles than their LDL-C would suggest, and it is most likely in men and in people with metabolic syndrome, diabetes, high triglycerides, or low HDL [6]. That is why apoB earns its place most clearly in metabolic syndrome and diabetes. That said, because apoB correlates closely with the standard numbers in most people, whether universal apoB testing is worth the added cost and clinician education is a genuine ongoing debate rather than a settled point. Strong that apoB is a better marker than LDL-C; contested whether it adds much over non-HDL cholesterol; moderate/contested on testing everyone.

One measurement caveat matters now that treatment targets are so low. LDL-C on a standard panel is usually calculated, not measured, and the old Friedewald formula systematically underestimates it precisely in the low-LDL, high-triglyceride range where decisions are now made. The newer Martin-Hopkins and Sampson (NIH) equations are more accurate there, and the 2026 US dyslipidemia guideline prefers either one over Friedewald [7]. In about 1.35 million US lab samples, among those with triglycerides of 2.3-4.5 mmol/L (200-399 mg/dL), a Friedewald LDL-C below 1.8 mmol/L (70 mg/dL) was confirmed by direct measurement only about 40% of the time, versus about 84% for Martin-Hopkins [8]. Fasting is no longer required for most routine panels; a fasting test is mainly for people whose non-fasting triglycerides are 4.5 mmol/L (400 mg/dL) or higher, who have a known or suspected triglyceride disorder, or who have a family history of a lipid disorder or early heart disease [9]. The practical targets, testing cadence, and treatment ladder live in lipid management and midlife labs; this page is about the underlying biology.

The biology: retention and cumulative exposure

Strong. Atherosclerosis is not fat passively clogging a pipe. It is an immune-inflammatory response to apoB particles becoming trapped in the artery wall. Once retained beneath the vessel lining, the particles oxidise, recruit immune cells (monocytes that mature into macrophages), and those macrophages engorge themselves on the oxidised lipid to become "foam cells." Foam cells die, forming the soft necrotic core of a plaque. This connects cholesterol directly to one of the integrative hallmarks of aging — chronic, low-grade inflammation.

The single most important consequence is that risk is cumulative. Each particle that crosses the artery wall has some probability of being trapped, so total plaque burden is the particle count multiplied by the years of exposure — an area under the curve, not a snapshot. This is why the question is never "is my cholesterol high right now?" but "how high has my particle count been, for how long?"

This is not just a marker correlation — it is one of the best-evidenced causal relationships in all of chronic-disease medicine. A European consensus panel triangulated meta-analyses of more than 200 prospective cohort studies, genetic (Mendelian randomization) studies, and randomised LDL-lowering trials — together covering over two million people — and found the same dose-dependent, straight-line relationship in every design, concluding that LDL does not merely track atherosclerosis but causes it. Strong / established consensus.[10] (The panel's meetings were supported by unrestricted grants from drug makers and several authors report industry ties, but the genetic arm of the evidence is funding-independent.)

It is also why lowering apoB earlier in life buys far more than the same reduction started in late middle age. A genetic analysis of more than 300,000 people found that each 1 mmol/L (39 mg/dL) lifelong lower LDL-C was tied to about a 55% lower risk of coronary heart disease, roughly three times the benefit seen per 1 mmol/L when a statin is started in mid or late life [11]. In the statin trials, which lasted about five years, each 1 mmol/L (39 mg/dL) drop cut the yearly rate of heart attacks, strokes and artery-opening procedures by just over a fifth [12]. The two numbers are not interchangeable: the genetic figure reflects decades of exposure and cannot be achieved by a pill started late — but it is the strongest available argument that "earlier is better." Real-world data now point the same way. In a Spanish study of families with inherited high cholesterol (familial hypercholesterolaemia), children and teenagers who started cholesterol-lowering drugs early (median age 14.5) had built up about 40% less lifetime LDL exposure by their 30s than their affected parents, who started at about 36. By age 39, 0.3% of the early-treated group had had a cardiovascular event, against 5.2% of the parents and none of their unaffected young relatives. This was an observational comparison across generations, not a trial, so changes in care over time may explain part of the gap [13]. Strong (genetic), with that interpretive caveat.

Remnant cholesterol: the residual risk in triglyceride-rich particles

Strong (genetic + epidemiology). Not all atherogenic particles are LDL. The cholesterol carried inside triglyceride-rich VLDL and IDL "remnants" — what's left as those particles are stripped down — is itself a causal driver of heart disease. A large genetic study in more than 70,000 people found that a rise in remnant cholesterol raised ischaemic heart disease risk independently of low HDL, and unlike LDL these remnants may not even need to be oxidised to be swallowed by artery-wall macrophages.[14] This is part of why apoB and non-HDL cholesterol outperform LDL-C: they count remnant particles that an LDL-C measurement misses. The important nuance is that what lowers risk is fewer apoB particles, not a lower triglyceride or remnant-cholesterol reading as such. In 10,497 adults with type 2 diabetes, raised triglycerides and low HDL cholesterol, the drug pemafibrate cut triglycerides and remnant cholesterol by about a quarter, but apoB rose slightly and major cardiovascular events did not fall (HR 1.03) [15]. The main positive triglyceride trial, of a high-dose purified fish-oil drug, is clouded because its mineral-oil placebo itself raised LDL-C and inflammation markers [16]. A newer drug that blocks apoC-III, olezarsen, cut triglycerides by more than half in people with moderately raised triglycerides, but it has been tested on triglyceride levels, not on heart attacks [17]. So the target is apoB/non-HDL-C, not chasing a triglyceride reading (covered in dietary fats).

Lipoprotein(a): the genetic wildcard

Strong / causal. Lipoprotein(a), written Lp(a), is an LDL-like particle with an extra protein tail (apolipoprotein(a)) that structurally resembles plasminogen, the molecule that dissolves clots. Lp(a) builds plaque and promotes inflammation, and particle for particle it is meaningfully more dangerous than ordinary LDL. Because of its resemblance to plasminogen it has long been suspected of promoting clots as well, but the European Atherosclerosis Society judges that role unproven in people [18]. Roughly one in five people inherit high levels. Lp(a) is more than 90% set by genes; it usually reaches adult levels by about age five, may creep up a little until adulthood, and then changes little, though in women it tends to rise at menopause [19]. Diet shifts it by only about 10-15% either way, and exercise and weight loss barely move it. Statins do not lower it and may nudge it up slightly (by about 1 mg/dL on average), which is no reason to stop one [20].

As a rough guide, a level below about 75 nmol/L (30 mg/dL) is low-risk. From about 125 nmol/L (50 mg/dL), the usual cut-off for "high", which about one in five people reach, risk is roughly 40% higher than at a typical level. At about 430 nmol/L (180 mg/dL), seen in about 1 in 100 people, it is about four times higher, similar to the inherited cholesterol disorder familial hypercholesterolaemia [21]. But the underlying relationship is continuous, so these cut-offs are a clinical convenience rather than true thresholds.

Because lifestyle barely moves it and a standard panel does not show it, US guidelines now recommend that every adult have it measured at least once. If yours is high, the guideline's answer for now is to bring LDL-C down harder than you otherwise would and to manage every other risk factor more tightly [22]. Drugs designed specifically to lower Lp(a) are now in large outcome trials: injections that cut it by roughly 70% to nearly 100% in earlier trials, and a pill, muvalaplin. But the pivotal question of whether lowering Lp(a) actually prevents heart attacks is still unanswered. The first to report, pelacarsen, lowered Lp(a) but did not significantly reduce cardiovascular events in 8,323 people with established cardiovascular disease and high Lp(a) (at least 70 mg/dL), according to topline results released in September 2026 [23]. The remaining injection trials are not expected to finish before 2028 [24], and the pill's trial not before 2031 [25]. Causality: strong; the therapies: promising for lowering Lp(a), unproven for outcomes. None is approved yet. What to do about an elevated result is covered in lipid management.

The paradoxes that confuse people

Three findings get cited as if they overturn the apoB story. None of them do — but each is real and worth understanding, because in each, a snapshot or a marker is being mistaken for lifelong cumulative exposure.

Very high HDL is not protective

Moderate (observational). HDL was long called "good cholesterol" because it carries cholesterol away from tissues back to the liver. The reality is a U-shaped curve for death from any cause: both low and very high HDL go with higher mortality, though the high end is less clear-cut than often claimed. In two Copenhagen cohorts of about 116,000 adults, death from any cause was lowest at an HDL of about 1.9 mmol/L (73 mg/dL) in men and 2.4 mmol/L (93 mg/dL) in women; compared with men at the lowest-risk level, those at 2.5-2.99 mmol/L (97-115 mg/dL) had about a third higher death rate (HR 1.36) and those at 3.0 mmol/L (116 mg/dL) or above about twice (HR 2.06), while in women a clear excess appeared only at 3.5 mmol/L (135 mg/dL) or above (HR 1.68) [26]. Pooling 17 cohorts with about 19.6 million people, extremely high HDL went with about 15% higher death from any cause (RR 1.15), but the rise in cardiovascular death was not statistically clear, and in women neither rose [27]. In a Korean cohort of about 115,000 adults aged 40-69 without diabetes, men with HDL above 2.1 mmol/L (80 mg/dL) had about 31% higher risk of dying from any cause than men at 1.0-1.6 mmol/L (40-60 mg/dL) after adjusting for the usual confounders (HR 1.31, a borderline result), an excess seen only in men under 60; women showed no such rise [28].

Very high HDL often signals dysfunctional particles that have lost their anti-inflammatory and cholesterol-offloading capacity, or is driven by heavy alcohol intake (which carries its own mortality). Crucially, drugs that raise HDL have repeatedly failed to reduce events in randomised trials — a whole class of HDL-raising agents (the CETP inhibitors) provides the falsification. Torcetrapib raised HDL by 72% and lowered LDL by about 25%, yet in 15,067 high-risk patients already on atorvastatin it was stopped early because the risk of death rose by about 58% (HR 1.58); it also raised blood pressure and aldosterone, an off-target effect the investigators suspected, though they could not rule out harm from the drug class itself [29]. Evacetrapib more than doubled HDL and also cut LDL, yet was halted for futility with no effect on events at all.[30] The one drug in this class that did modestly reduce events in a large outcome trial, anacetrapib, cut major coronary events by about 9% (10.8% vs 11.8%; rate ratio 0.91) over about four years in 30,449 people with atherosclerotic disease already on intensive statins; it doubled HDL but also lowered non-HDL cholesterol by 18%, and its small benefit is in line with that fall [31]. Genetic studies point the same way: in about 103,000 people, gene variants that mimic this drug class lowered the risk of major cardiovascular events only in proportion to how far they lowered apoB [32]. The lesson: HDL is a marker of metabolic state, not a lever to pull — and the old idea that alcohol's HDL-raising effect protects the heart has collapsed under genetic analysis.

Low cholesterol in the very old

Moderate — most likely reverse causation, not fully settled. In people in their late 80s and 90s, higher total cholesterol and LDL-C often go with lower death rates over the next few years, the opposite of the midlife pattern. Among 168 people aged 90 and over in Sardinia's longevity hot spot, those with LDL-C of 3.4 mmol/L (130 mg/dL) or more lived about a year longer on average over six years of follow-up [33]. Among 903 Chinese adults aged 85 and over, total cholesterol of 3.4 mmol/L (131 mg/dL) or more went with about 30% lower death rates over three years (HR 0.71-0.72), though in the study's own curves the link was not statistically clear at any single level [34]. Both are small studies built on a single cholesterol reading taken in old age, and the Sardinian authors argue the pattern is real rather than an artefact. The usual explanation is reverse causation: serious illness, frailty, malnutrition and hidden cancer all lower cholesterol, so a low reading in the very old often marks decline rather than causing it. Even at ages 70-89, each 1 mmol/L (39 mg/dL) lower total cholesterol still went with about a sixth fewer heart-disease deaths (HR 0.83) across 61 cohorts of almost 900,000 adults free of heart disease at the start [35].

A widely shared review has been used to argue this pattern disproves the cholesterol story altogether: of 28 cohorts of people over 60, it counted 16 where higher LDL-C went with lower overall mortality and found no link in the rest [36]. An independent appraisal by Oxford's Centre for Evidence-Based Medicine found serious weaknesses: no predefined protocol, a search of a single database that excluded 263 of 282 screened articles without per-study reasons, no meta-analysis, and no control for confounding (for example, people with high LDL-C starting statins during follow-up), which it judged more likely to explain most of the inverse associations. About two-thirds of the participants also came from a single study [37]. It cannot outweigh the genetic and trial evidence.

This does not contradict the lifelong story. Genetic studies, which capture decades of exposure rather than one frail year, point the same way. In a Mendelian randomisation study drawing on lifespan data for about a million people, genetically higher LDL-C (by one standard deviation) meant about 1.2 years shorter life [38]. In UK Biobank, people carrying genes for about 0.24 g/L higher apoB had parents who died roughly half a year to a year earlier, and about 2 years earlier once LDL-C and triglycerides were accounted for [39]. Low cholesterol in a 95-year-old can mean illness; low cumulative apoB across a lifetime means protected arteries. They are not the same measurement. And in healthy older people LDL-C still matters for the heart. In a Danish cohort of 91,131 adults aged 20-100 with no heart disease or diabetes and not on statins, higher LDL-C went with higher heart-attack risk at every age, and the number of extra heart attacks linked to it was highest at 70-100. Among those aged 80-100, LDL-C of 5 mmol/L (193 mg/dL) or more meant about three times the heart-attack risk of LDL-C below 3 mmol/L (116 mg/dL) (HR 2.99) [40]. See Blue Zones for how to read longevity-population data without over-fitting.

Keto and the Lean-Mass Hyper-Responder

Weak / preliminary — flag the uncertainty. A specific group of lean, fit, metabolically healthy people who adopt a ketogenic (very-low-carbohydrate) diet develop a striking triad: very high LDL-C (often above 4.9 mmol/L / 190 mg/dL, sometimes far higher), high HDL, and low triglycerides. These are the "Lean-Mass Hyper-Responders." The proposed mechanism — the Lipid Energy Model — is that with carbohydrate scarce, a lean liver ships large amounts of fat to muscle for fuel via triglyceride-rich particles that remodel into many LDL particles; the leaner the person, the higher the LDL spike.

The reassuring data are thin. In a single snapshot scan, 80 hyper-responders (average age about 55, on keto for about 4.7 years, average LDL-C about 7.0 mmol/L (272 mg/dL)) had no more coronary plaque than 80 matched people with LDL-C around 3.2 mmol/L (123 mg/dL). But both groups had very little plaque, and a single scan cannot show whether plaque is growing [41]. A one-year follow-up from the same study, which claimed that plaque growth was predicted by existing plaque and not by apoB, was retracted in 2026 at the request of the authors and the editors because of errors in its methods [42]. Across randomised trials in adults aged 35-75 with at least one cardiovascular risk factor, ketogenic diets raised LDL-C by about 0.4 mmol/L (17 mg/dL) on average compared with low-fat, moderate-carbohydrate diets [43]. There are no outcome data for this phenotype, and a few years of follow-up is short for a disease that takes decades. The honest position is uncertainty, not reassurance: hyper-responders who want to stay in ketosis but not gamble on unproven long-term risk can lower apoB with a cholesterol-absorption inhibitor (ezetimibe).

What actually moves your lipids

Moderate. Lifestyle reliably improves the lipid profile, but the effect sizes are modest — for someone with genuinely high apoB, pharmacology does the heavy lifting. The lifestyle levers still matter because they act for decades and improve much more than lipids.

  • Diet. The dominant dietary lever is substitution. In long-term randomised trials in 53,758 adults with or without heart disease, cutting saturated fat for at least two years modestly lowered LDL-C and led to about 17% fewer combined cardiovascular events (RR 0.83), though not clearly fewer deaths; the trials suggested a benefit whether saturated fat was replaced with polyunsaturated fat (about 21% fewer events) or with carbohydrate (about 16% fewer), with no clear difference between the two [44]. The trials did not separate refined from whole-food carbohydrate, so they cannot say whether sugar and white starch are as good a swap. Dietary cholesterol itself (eggs, shellfish) matters less than once thought: in feeding studies, eating more than today's average raises total and LDL cholesterol modestly, but large observational studies generally find no link with heart disease, and current advice focuses on overall eating patterns rather than a numeric cholesterol limit [45]. Detail lives in dietary fats and dietary patterns.
  • Exercise. Training nudges the whole panel in the right direction, but only a little: across 148 randomised trials in 8,673 adults, exercise lowered LDL-C by about 0.19 mmol/L (7 mg/dL) and triglycerides by about 0.09 mmol/L (8 mg/dL) and raised HDL-C by about 0.05 mmol/L (2 mg/dL). Aerobic and combined aerobic-plus-resistance training lowered LDL-C, resistance training on its own mainly raised HDL-C, and combining the two worked best [46]. Exercise may also lower apoB when LDL-C barely moves: in a one-year trial in 188 overweight, healthy men aged 40-49, endurance training lowered apoB while LDL-C did not change significantly [47]. Even prolonged sitting matters — it collapses the muscle enzyme (lipoprotein lipase) that clears triglycerides from the blood.
  • Sleep and circadian rhythm. The links here are weaker and come from observational studies. In a cohort of 34,260 Chinese adults who started without lipid problems, sleeping 9 hours or more was linked to about 24% higher risk of developing low HDL-C than sleeping 7 hours (HR 1.24), but sleep length was not linked to later high LDL-C, total cholesterol or triglycerides [48]. Body-clock disruption may matter on its own: among 921 male underground miners, night-shift workers had slightly higher total cholesterol than day workers (5.36 vs 5.09 mmol/L, about 207 vs 197 mg/dL), including those who said they slept well, though a one-time snapshot like this cannot show cause [49]. Keeping a regular circadian rhythm is a sensible part of looking after your lipids.
  • Stress. Acute psychological stress transiently raises cholesterol and triglycerides through the stress-hormone axis, and chronic stress sustains the pattern; structured stress reduction modestly improves the profile.

How clinicians turn all of this into a personal plan — formal cardiovascular-risk scoring (such as Europe's SCORE2, which estimates 10-year risk of fatal and non-fatal events), apoB targets by risk tier, and when drugs are warranted — sits in lipid management. The unifying principle is "lower and earlier is better" for apoB across the whole adult lifespan.

Does lowering apoB actually help? The outcome evidence

Strong. The whole page rests on the claim that apoB builds plaque; the payoff is that lowering it prevents events, whether through statins or through several non-statin drugs. Statins are the anchor: pooling data from many trials, each 1 mmol/L (39 mg/dL) drop in LDL-C lowered the yearly rate of major vascular events by just over a fifth (rate ratio 0.78) in trials lasting about five years, with no lower threshold at which the benefit ran out and no excess of cancer or non-vascular death.[50] That principle (fewer apoB-carrying particles, fewer events) is confirmed by non-statin drugs: adding ezetimibe, which blocks cholesterol absorption, cut events further,[51] and the injectable PCSK9 inhibitors, which push LDL-C to very low levels, reduced major events by about 15% in people with established heart or artery disease.[52] A second PCSK9 trial showed a nominal reduction in death, though the trials were short (two to three years), which likely limits how large a mortality signal they can show.[53] Evolocumab, the drug tested in the first PCSK9 trial, also prevents first events. In 12,257 people with narrowed arteries or high-risk diabetes who had never had a heart attack or stroke and had an LDL-C of at least 2.3 mmol/L (90 mg/dL), evolocumab cut coronary deaths, heart attacks and ischaemic strokes by about a quarter (HR 0.75) over a median of 4.6 years, from 8.0% to 6.2% at five years, with no difference in side effects [54]. Not every LDL-lowering drug pays off, as the CETP inhibitors above show. Bempedoic acid, an oral option for people at high heart risk who are unable or unwilling to take statins because of side effects, cut major heart events by about 13% (HR 0.87) in a trial of nearly 14,000 such people. It did not measurably reduce deaths, and it slightly raised gout and gallstones (gout about 3% vs 2%) [55]. In the roughly 4,200 participants with no known heart or artery disease (average age 68, two-thirds with diabetes), the reduction looked larger, about 30% (HR 0.70), but this was a subgroup analysis that the investigators themselves call hypothesis-generating [56]. Newer agents such as the twice-yearly injectable inclisiran reliably lower LDL-C by about half, but their outcome trials are still running, so they remain emerging for hard endpoints.[57] All of these pivotal trials are industry-funded; the strongest funding-independent support comes from the genetic and academic meta-analytic work above. Detailed dosing and choice of agent live in lipid management.

Two safety questions dominate the public debate and deserve a straight answer. Muscle aches are the most-cited reason people quit statins, but in large blinded trials they were almost as common on placebo. Across 19 trials with about 124,000 people, 27.1% of those on a statin and 26.6% of those on placebo reported muscle pain or weakness. The researchers estimated that more than 90% of muscle complaints among people taking a statin were not caused by the drug; the small real excess was mostly mild and appeared mainly in the first year [58]. Trials in people who had already given up statins because of side effects point the same way. In one, a dummy pill produced about 90% of the extra symptoms the statin did [59]. In a series of 200 people who had stopped or were thinking of stopping because of muscle symptoms, symptom scores did not differ between statin and placebo months [60]. This is the nocebo effect — the symptoms are real, but the molecule is usually not the cause. New-onset diabetes is a genuine drug effect. Across 19 placebo-controlled trials with about 124,000 people, statins raised the chance of a new diabetes diagnosis among those who did not already have it by about 10% on low- or moderate-intensity doses (rate ratio 1.10) and by about a third on high-intensity doses (rate ratio 1.36). This reflects a small average rise in blood sugar, about 0.04 mmol/L (0.7 mg/dL), and most of the new diagnoses were in people who were already close to the diagnostic threshold. Any harm from that rise is already counted in the trials' overall drop in heart attacks and strokes, so the vascular benefit outweighs it [61]. A parallel worry, that very low LDL-C harms the brain, has not shown up. In 1,204 people with heart disease already on statins, adding evolocumab did not change memory or thinking scores over a median of 19 months [62]. In an open-label extension, 473 trial participants then took evolocumab for a median of about five more years, at a median LDL-C of about 0.9 mmol/L (35 mg/dL), and their thinking scores did not decline; the authors note this still needs testing in people at higher risk of dementia [63]. Pooled blinded statin trials (19 trials, about 124,000 people) found no excess of cognitive impairment [64]. The trial meta-analyses also found no excess cancer, though follow-up is measured in years, not decades. Strong (no harm signal), tempered by finite follow-up.

For a longevity reader, the sharpest question is when. Statins clearly help for primary prevention up to about age 75. Above 70 there is now direct trial evidence, and it is mixed. Among 9,971 community-dwelling adults aged 70 or older with no heart disease, diabetes or dementia, atorvastatin 40 mg a day cut heart attacks, strokes and related events by about 30% (HR 0.70) over a median of 5.9 years. It did not help people live longer free of dementia or disability (HR 0.94, not statistically significant). Serious side effects were equally common on statin and placebo, at 2.7% each, though muscle, liver and diabetes-related problems were more frequent on the statin [65]. A second, larger trial in people aged 75 and older (PREVENTABLE) is still under way [66]. The useful lens is time-to-benefit. A meta-analysis of more than 65,000 adults aged 50-75 estimated it takes about 2.5 years of treatment to prevent one cardiovascular event per 100 people, and only one of its eight trials found fewer deaths from any cause [67]. The practical rule follows directly: a primary-prevention statin makes sense when remaining life expectancy comfortably exceeds the time-to-benefit — which is also why deprescribing becomes reasonable in frailty or limited life expectancy. Strong for primary prevention through 75; from 70 on, a trial shows fewer heart events but no gain in years lived free of dementia or disability.

Where the CT scan fits: coronary artery calcium

Strong as a predictor; randomised trials of scan-guided care have not yet shown fewer heart attacks or deaths. A coronary artery calcium (CAC) scan counts established, calcified plaque, and it can sharpen the decision of who most needs lipid-lowering. In a retrospective study of 13,644 adults scanned at a US military hospital (average age 50, mostly men), statin users with a zero score did no better than non-users over about 10 years, while among those with a score above 100, treating about 12 people for a decade prevented one heart attack, stroke or cardiovascular death; this was an observational comparison, so healthier habits among statin takers may explain part of it [68]. In studies that screened people without symptoms and acted on the score, LDL-C fell only slightly more than with usual care, by about 0.13-0.16 mmol/L (5-6 mg/dL), and none of the three studies that tracked heart events or deaths could show a difference, mainly because events were few, follow-up short or samples small [69]. A zero score, though, is not a clean bill of health: it measures only the hardened, late-stage plaque, not the soft, lipid-rich early lesions this page describes. It is least reassuring in people over 40 with diabetes, current smokers, people with familial hypercholesterolaemia or LDL-C above 4.9 mmol/L (190 mg/dL), and those with a strong family history of early heart disease; guidelines say a zero score should not be used to withhold a statin in these groups [70]. A zero score also has a shelf life: in a large US cohort of people with an initial zero (average age 58), about half had developed some calcium within 10 years, and about one in five of the coronary events they had over that decade struck before a repeat scan at 3-5 years [71]. Treat it as a tie-breaker that refines apoB-based decisions, not a substitute for them.

What's overrated

  • Chasing a high HDL. It is a marker, not a target; very high levels can signal dysfunction, and HDL-raising drugs don't improve outcomes through the HDL rise.
  • Fixating on a single LDL-C reading. One number on one day says little. Lifelong apoB exposure is the quantity that builds plaque.
  • Dietary-cholesterol panic. Eggs and shellfish raise blood cholesterol only modestly, and large cohorts find no clear link with heart disease; the dietary pattern and saturated-fat substitution dominate.
  • Reading the paradoxes as a green light. Low cholesterol in the frail elderly and the keto hyper-responder findings are interesting nuances at the edges — not licence for a healthy midlife adult to ignore a high apoB.

Further reading

  • A Meta-Analysis of LDL-C, Non-HDL-C, and Apolipoprotein B as Markers of Cardiovascular Risk. Circ Cardiovasc Qual Outcomes 2011.[72]
  • Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies — European Atherosclerosis Society consensus. Eur Heart J 2017.[73]
  • Effect of long-term exposure to lower LDL-C beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. JACC 2012.[74]
  • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials — Cholesterol Treatment Trialists. Lancet 2010.[75]
  • Remnant cholesterol as a causal risk factor for ischemic heart disease. JACC 2013.[76]
  • N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects (SAMSON). NEJM 2020.[77]
  • Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years. JAMA Intern Med 2021.[78]
  • Association between very high HDL-C levels and mortality: a systematic review and meta-analysis.[79]
  • The Cholesterol Paradox in Long-Livers from a Sardinia Longevity Hot Spot (Blue Zone).[80]
  • Low-density lipoprotein cholesterol and lifespan: a Mendelian randomization study.[81]
  • Effects of apolipoprotein B on lifespan and risks of major diseases: a Mendelian randomisation analysis.[82]
  • Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial. JACC Adv 2024.[83]
  • Reduction in saturated fat intake for cardiovascular disease. Cochrane systematic review.[84]
  • The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis.[85]
— § —